Diurnal Group PLC Hardman Research: Alkindi®: On route to Europe

TIDMDNL

Diurnal Group PLC

19 December 2017

Hardman Research: Alkindi(R): On route to Europe

Alkindi(R): On route to Europe: Diurnal is a clinical stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead candidates are targeted at rare diseases with unmet medical need, with the aim of building a long-term 'Adrenal Franchise'. Following successful completion of a Phase III trial, Alkindi(R) (previously known as Infacort(R)) has received a positive opinion from the CHMP, recommending the granting of market authorisation for replacement therapy in adrenal insufficiency for children from birth up to 18 years of age. The European Commission is expected to grant market approval in February, allowing first sales in 2Q 2018.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/diurnal-ltd-documents/19-12-17-diurnal.pdf

 
 To contact us:         Analysts: 
  Hardman & Co           Dr Martin Hall mh@hardmanandco.com 
  35 New Broad Street    Dr Dorothea Hill dmh@hardmanandco.com 
  London                 Dr Gregoire Pave gp@hardmanabdco.com 
  EC2M 1NH               Telephone: +44 20 7194 7622 
                         Follow us on Twitter @HardmanandCo

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAFFUFEUFWSELE

(END) Dow Jones Newswires

December 19, 2017 07:53 ET (12:53 GMT)

Diurnal (LSE:DNL)
Historical Stock Chart
From Mar 2024 to Apr 2024